LED 頭皮・頭髪ケアデバイス

CLINICAL EVIDENCE THROUGH TRIALS

Clinical Safety and Efficacy of an At-Home, Dual Wavelength Red Light Hair Growth System in Subjects with Androgenetic Alopecia. (Sinclair, 2020)

81 subjects were paired with a Bluetooth-connected mobile app (LED system) or a sham comparator device with a similar user experience through the mobile app to track daily treatment compliance between both groups. Device usage was fixed at once daily, 10-minute treatment durations for a period of 26 weeks. The trial population consisted of adult men and women between 18 and 65 years of age with a diagnosis of androgenetic alopecia, consistent with males who have Norwood Hamilton Classification IIa to V patterns of hair loss and females who have Ludwig-Savin Scale I-1 to I-4, II -1, II-2 or frontal.

Summary: After 16 weeks, subjects that were treated with the dual wavelength red light device and were at least 80% compliant (n=18) had a mean change of 26.3 more hairs per cm² compared to those participants who wore a sham cap, identical in appearance but received no light therapy (n=18).

INCREASE IN HAIR COUNT COMPARISON

(640nm) LED versus:

Laser Hair Growth Device - (Jimenez et al.) Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study. American Journal of Clinical Dermatology 2014. PubMed Reference.

Minoxidil: (Olsen et al.) A multicenter, randomised, placebo-controlled, double-blind clinical trial of a novel formulation of 5% Minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology 2007. PubMed Reference.

Finasteride: (Leyden et al.) Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology 1999. PubMed Reference.

CLINICAL EVIDENCE THROUGH INDEPENDENT LABORATORY TESTING

Independent Laboratory Testing conducted by Intertek Testing Services Ltd., Shanghai (September 2023)

NO.: CRS-2023-157-ZH-01-1EN

DATE: SEP. 18, 2023

25 subjects, men and women aged between 18 and 55, continuously used the test sample for 84 days to measure hair loss prevention and growth improvement.

Using several assessments, including clinical assessments and a questionnaire, tested parameters such as moisture content, oil content, hair loss counts, hair density and hair growth rate of the scalp.